Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Theaphenon 95% in Multiple Sclerosis
NCT02011451Phase 2Withdrawn
- Sponsor
- Louisiana State University Health Sciences Center
- Start
- Dec 2015
- Primary completion
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Theaphenon 95 in multiple sclerosis (MS) (2 arms), sponsored by Louisiana State University Health Sciences Center. Primary endpoint: Rate of change in N-Acetyl-Aspartate levels adjusted for water content at 6 months. Planned start Dec 2015; status: withdrawn.
02
Drugs
Theaphenon 95
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT02011451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02011451.